LONDON – The EMA has opened a public consultation on moves to get its processes working in parallel with health technology assessment (HTA) bodies, with the aim of providing drug developers with scientific advice that enables them simultaneously to generate safety and efficacy data for the marketing authorization and evidence of the value-added for HTAs.